Market Research Industry Reports

Hyperinsulinemia - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Hyperinsulinemia - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Pipeline Review, H2 2017, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Hyperinsulinemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperinsulinemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperinsulinemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperinsulinemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperinsulinemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperinsulinemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperinsulinemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperinsulinemia - Overview
Hyperinsulinemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperinsulinemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperinsulinemia - Companies Involved in Therapeutics Development
Crinetics Pharmaceuticals Inc
Eiger BioPharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
Heptares Therapeutics Ltd
Rezolute Inc
Zealand Pharma AS
Hyperinsulinemia - Drug Profiles
ABGLC-035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exendin-(9-39) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exendin-(9-39) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15136 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR5 for Hyperinsulinemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNB-2401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperinsulinemia - Dormant Projects
Hyperinsulinemia - Product Development Milestones
Featured News & Press Releases
Jan 31, 2017: XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery
Oct 19, 2016: XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism
Sep 15, 2016: XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies
Jul 20, 2016: XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism
Jun 16, 2015: XOMA Receives Orphan Drug Designation for XOMA 358 From U.S. FDA for Treatment of Congenital Hyperinsulinism (HI)
Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Hyperinsulinemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, H2 2017
Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Hyperinsulinemia - Pipeline by Heptares Therapeutics Ltd, H2 2017
Hyperinsulinemia - Pipeline by Rezolute Inc, H2 2017
Hyperinsulinemia - Pipeline by Zealand Pharma AS, H2 2017
Hyperinsulinemia - Dormant Projects, H2 2017

List Of Figures


Number of Products under Development for Hyperinsulinemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Hyperinsulinemia - Pipeline Review, H2 2017

Hyperinsulinemia - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Pipeline Review, H2 2017, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline

USD 2000View Report

Hyperinsulinemia Global Clinical Trials Review, H2, 2017

Hyperinsulinemia Global Clinical Trials Review, H2, 2017GlobalDatas clinical trial report, Hyperinsulinemia Global Clinical Trials Review, H2, 2017 provides an overview of Hyperinsulinemia clinical trials scenario. This report provides top line

USD 2500View Report

Lysosomal Alpha Glucosidase Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20 - Pipeline Review, H1 2018

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Review, H1 2018According to the recently published report Lysosomal Alpha Glucosidase - Pipeline Review, H1

USD 3500View Report

Beta Secretase 1 Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46 - Pipeline Review, H1 2018

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) -

USD 3500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Dec 2017
No. of Pages :46
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube